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Primary prevention of bacterial meningitis—predomi-
nantly through vaccination programs—is of paramount
importance, since mortality and long-term disabling
sequelae remain substantial [1]. Routine vaccination also
offers herd immunity for the unvaccinated population [2].
The most illustrative example of such a major impact is the
introduction of meningococcal conjugate vaccines [3].
Vaccination against serogroup A in Africa and sero-
group C in Europe have decreased its incidence by 95 % or
more [3]. A novel, four-component, recombinant,
meningococcal serogroup B vaccine was shown to be
immunogenic and safe in two randomized controlled trials
testing infants and children [4]. Implementation of this
vaccine may further decrease invasive meningococcal
disease, but decreasing rates of penicillin susceptibility and
the possible resurgence of the disease remain a public
health threat [5]. Of concern is a recent international out-
break of MenC:cc11 disease among gay men, and the
demonstrated expansion of MenW:cc11 disease in England
and Wales, South Africa, and South America, which were
associated with high case fatality rates [6]. Overall, the
implementation of vaccines has resulted in a clear decrease
in bacterial meningitis incidence in the past 20 years [7].
The recognition of urgency in acute bacterial meningitis
remains problematic despite the certitude of the diagnosis
and even in the setting of clinical trials delays in antibiotic
initiation have been documented [8]. The maxim ‘‘time is
brain’’ also applies to potentially ravaging bacterial central
nervous system infections. Neuroimaging before lumbar
puncture—perhaps ordered in more vexing presenta-
tions—is an important delay in administration of IV
antibiotics and corticosteroids. A recent analysis suggests
improvement in early antibiotic administration is feasible
using clinical judgment rather than rigid protocols [9]. If
imaging is performed before lumbar puncture, empiric
treatment with antibiotics and, when indicated, dexam-
ethasone should be administered before the patient is sent
for neuroimaging. Moreover, blood cultures should be
drawn because they identify the causative organism in
50–80 % cases [7, 10]. Dexamethasone therapy has been
shown to be beneficial on a nationwide level, but has also
been associated with secondary deterioration in sporadic
patients. The cause of this delayed cerebral thrombosis
remains to be elucidated but prolonged immunosuppres-
sive therapy is currently advised [11].
Randomized clinical trials (RCTs) have recently eval-
uated several adjunctive therapies in meningitis.
Antipyretic treatments are often administered in severely
ill patients, but RCTs of 723 children with bacterial
meningitis in Luanda, Angola, and 360 children in
Malawi, showed that paracetamol did not increase sur-
vival [12, 13] (Table 1). Case series reported favorable
effects of moderate hypothermia in bacterial meningitis,
but one RCT showed that moderate hypothermia did not
improve outcome in patients with severe meningitis, and
even suggested harm [14]. Initial RCTs suggested that
glycerol could reduce hearing loss and neurologic
sequelae in children with bacterial meningitis [15].
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However, in 2011, an RCT in Malawian adults with
bacterial meningitis was stopped early because of higher
mortality in the glycerol-treated patients as compared to
placebo (63 vs. 49 %) [16]. A subsequent study from
Malawi, including 360 children with bacterial meningitis,
also showed no benefit of glycerol with comparable
mortality, rates of hearing loss, and sequelae in glycerol-
and placebo-treated patients [12].
Some have advocated early intracranial pressure
monitoring, aggressive treatment of brain edema with
high doses of corticosteroids, osmotic diuretics, decom-
pressive craniectomy, and ventriculostomy when there is
hydrocephalus, but there is no conclusive evidence of
improved outcome except in anecdotal cases [17–19]. The
most important variable is initial management and
appropriate treatment with antibiotics within an hour of
arrival in the emergency department.
Seizures occur in 17 % of adults with bacterial
meningitis and are associated with poor outcome [20].
Seizures and status epilepticus (non-convulsive and con-
vulsive) require immediate attention, but treatment must
be better defined. Detection of seizures may require
continuous EEG monitoring but management of periodic
epileptiform discharges—once found—has not been pro-
ven to change outcome and serious concerns remain about
over-aggressiveness and side effects of anesthetics.
Patients with fulminant bacterial meningitis are criti-
cally ill and can survive with neurointensive care. Septic
shock accompanies acute bacterial meningitis in 20 %
and may progress rapidly when antibiotic treatment is
delayed [19, 21]. Early intensive care treatment of septic
shock is pertinent to avoid death from multiorgan failure.
New developments in bacterial meningitis research
include genetic association studies that have identified
genetic variation in the complement activation to influ-
ence both susceptibility and outcome of disease [22]. This
has led to new adjunctive treatment strategies such as
complement inhibition, which may be tested in bacterial
meningitis patients in the upcoming years [22]. Other
preclinical research includes inhibitors of metallopro-
teinases which were shown to decrease brain damage in
experimental studies [23]. Finally, evaluation of different
antibiotic regimens may shed light on whether bacterio-
static antibiotics such as rifampicin have a superior
efficacy compared to bacteriolytic regimens [24].
To epitomize, the incidence of bacterial meningitis has
been decreasing owing to the development of effective
vaccines in the past decades. Widespread introduction of
conjugate vaccines, especially where disease burden is
greatest, is likely to further decrease the global burden of
acute bacterial meningitis. There is still an urgent need for
new treatment options and refinement of emergency and
neurocritical care. Delay in diagnosis and treatment
remain the major concerns in the management of acute
bacterial meningitis. De-escalation of care may be the



















































































































































































































































































































































































































































































































































comatose after fulminant meningitis. Early withdrawal
may be inappropriate because even patients who are
nearly moribund may actually survive and some of them
may fully recover.
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